
Sensus Healthcare (SRTS) Stock Forecast & Price Target
Sensus Healthcare (SRTS) Analyst Ratings
Bulls say
Sensus Healthcare Inc. demonstrated significant growth in its shipping operations, delivering 27 SRT systems in 3Q24, a notable increase from previous quarters, highlighting the company's expanding market reach and demand. The company's financial performance for FY2024 was strong, with total revenue of $41.8 million, reflecting a remarkable 71% year-over-year growth, coupled with a net income of $6.6 million, further reinforcing its solid financial position. Additionally, the successful signing of multiple Fair Deal Agreements, including one with a network of over 130 dermatology clinics, emphasizes the company's strategic initiatives poised to enhance revenue streams and solidify its foothold in the market.
Bears say
Sensus Healthcare faces significant investment risks that could hinder its financial performance, particularly concerning the commercial success of its SRT and TransDermalInfusion systems. The company's ability to penetrate the market successfully is threatened by potential reimbursement issues and increased competition in the health technology sector. Additionally, there is a risk of dilution which may negatively impact shareholder value and overall financial stability.
This aggregate rating is based on analysts' research of Sensus Healthcare and is not a guaranteed prediction by Public.com or investment advice.
Sensus Healthcare (SRTS) Analyst Forecast & Price Prediction
Start investing in Sensus Healthcare (SRTS)
Order type
Buy in
Order amount
Est. shares
0 shares